Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;59(3):329-333.
doi: 10.1080/0284186X.2019.1684560. Epub 2019 Oct 31.

17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study

Lindsay J Collin  1 , Sinna P Ulrichsen  2 , Thomas P Ahern  3 , Michael Goodman  1 , Lauren E McCullough  1 , Lance A Waller  4 , Kristina Bang Christensen  5 , Per Damkier  6   7 , Stephen Hamilton-Dutoit  5 , Kristina L Lauridsen  5 , Rami Yacoub  1 , Peer M Christiansen  8 , Bent Ejlertsen  9   10 , Henrik Toft Sørensen  2   11 , Deirdre P Cronin-Fenton  2 , Timothy L Lash  1   2
Affiliations

17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study

Lindsay J Collin et al. Acta Oncol. 2020 Mar.

Abstract

Background:: Approximately 20–40% of patients diagnosed with breast cancer will experience a recurrence up to 20 years after their original diagnosis. 17?-hydroxysteroid dehydrogenase 1 and 2 (HSD17B1 and HSD17B2, respectively) regulate intratumoral concentrations of oestradiol, which promotes growth and proliferation of hormone dependent tumours. Breast carcinomas with increased HSD17B1, without a corresponding increase in HSD17B2, expression may become resistant to tamoxifen therapy by producing locally higher concentrations of oestradiol, which compete with tamoxifen and its metabolites for binding to the oestrogen receptor (ER).

Materials and Methods:: In this population-based case-control study, we included women diagnosed with stage I–III breast cancer between 1985 and 2001, aged 35–69 years, registered in the Danish Breast Cancer Group. We identified 541 cases of breast cancer recurrence among women with ER positive disease who were treated with tamoxifen for at least 1 year (ER+TAM+). We also enrolled 300 breast cancer recurrence cases among women with ER negative disease, not treated with tamoxifen, who survived at least 1 year (ER?/TAM?). Controls were recurrence-free breast cancer patients at the time of case diagnosis, matched to recurrence cases on ER/TAM status, date of surgery, menopausal status, stage, and county or residence. Expression of HSD17B1 and HSD17B2 were measured by immunohistochemistry on tissue microarrays. We fit logistic regression models to compute odds ratios (ORs) and 95% confidence intervals (CIs) associating the HSD17B1:HSD17B2 ratio (>1 vs. ?1)—and each enzyme’s independent expression—with recurrence.

Results:: We found no association between the HSD17B1:HSD17B2 ratio and breast cancer recurrence in either ER/TAM stratum (ER+/TAM+: OR=1.03, 95% CI: 0.78, 1.40; ER?/TAM?: OR=1.02, 95% CI: 0.77, 1.19). Associations for expression of each individual enzyme were also near null.

Conclusion:: The ratio of HSD17B1 expression to HSD17B2 expression was not associated with breast cancer recurrence in this study.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement:

The authors have no conflict of interest to declare.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. - PubMed
    1. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017;377(19):1836–1846. - PMC - PubMed
    1. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106(5). - PMC - PubMed
    1. Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76(1):27–36. - PubMed
    1. Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016;34(25):3069–103. - PubMed